Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19305413.
- Also identified by DOI 10.1038/nm.1941.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibitors of alpha(v)beta(3) and alpha(v)beta(5) integrin have entered clinical trials as antiangiogenic agents for cancer treatment but generally have been unsuccessful. Here we present in vivo evidence that low (nanomolar) concentrations of RGD-mimetic alpha(v)beta(3) and alpha(v)beta(5) inhibitors can paradoxically stimulate tumor growth and tumor angiogenesis. We show that low concentrations of these inhibitors promote VEGF-mediated angiogenesis by altering alpha(v)beta(3) integrin and vascular endothelial growth factor receptor-2 trafficking, thereby promoting endothelial cell migration to VEGF. The proangiogenic effects of low concentrations of RGD-mimetic integrin inhibitors could compromise their efficacy as anticancer agents and have major implications for the use of RGD-mimetic compounds in humans.
Medical subject headings
- Angiogenesis Inhibitors
- Integrin alphaVbeta3
- Lung Neoplasms
- Melanoma, Experimental
- Receptors, Vitronectin